ELYM Eliem: רווח נקי למניה ב-12 החודשים האחרונים

Eliem Therapeutics' reliance on outsourcing molecule synthesis via CMOs drives volatility, as evidenced by the comparable year-over-year growth in EPS TTM. Meanwhile, 18.60 represents the latest reading of this metric. The creation of a neural disorder therapy ecosystem strengthens the issuer's position, while a high reputation among neurobiologists in the field of insomnia treatment ensures the loyalty of specialized investors.
Eliem - פילוחים אנליטיים ומדדי מפתח (ELYM)

This metric is sensitive to the dynamics of operating expenses and net income, measuring the annual growth rate of earnings per share over a rolling period. For Eliem Therapeutics (ELYM), the absence of proprietary manufacturing plants and the reliance on external drug synthesis directly impact margins. The efficiency of outsourcing determines the final profitability. By analyzing the YoY EPS change on a rolling 12-month basis, an investor assesses the sustainability of this business model.